Healthcare provider profile · identity verified

Major Ryan Gross, MD

Internal Medicine · BREMERTON, WA · NPI 1326035387

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	530	161
Amlodipine Besylate	Amlodipine Besylate	425	122
Losartan Potassium	Losartan Potassium	321	90
Levothyroxine Sodium	Levothyroxine Sodium	312	70
Metoprolol Succinate	Metoprolol Succinate	289	83
Tramadol Hcl	Tramadol Hcl	288	57
Potassium Chloride	Potassium Chloride	194	59
Lisinopril	Lisinopril	182	55
Omeprazole	Omeprazole	163	46
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	158	30
Simvastatin	Simvastatin	154	42
Gabapentin	Gabapentin	150	46
Metformin Hcl	Metformin Hcl	135	43
Sertraline Hcl	Sertraline Hcl	120	29
Pantoprazole Sodium	Pantoprazole Sodium	117	32
Tamsulosin Hcl	Tamsulosin Hcl	110	36
Furosemide	Furosemide	106	37
Alprazolam	Alprazolam	94	23
Allopurinol	Allopurinol	89	22
Jardiance	Empagliflozin	88	27
Hydrochlorothiazide	Hydrochlorothiazide	85	30
Trazodone Hcl	Trazodone Hcl	84	26
Chlorthalidone	Chlorthalidone	82	25
Oxycodone Hcl	Oxycodone Hcl	81	18
Prednisone	Prednisone	76	31
Xarelto	Rivaroxaban	75	17
Zolpidem Tartrate	Zolpidem Tartrate	73	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	71	20
Clopidogrel	Clopidogrel Bisulfate	69	19
Atenolol	Atenolol	65	16
Rosuvastatin Calcium	Rosuvastatin Calcium	64	24
Duloxetine Hcl	Duloxetine Hcl	63	13
Eliquis	Apixaban	62	17
Fluoxetine Hcl	Fluoxetine Hcl	59	14
Mirtazapine	Mirtazapine	59	13
Albuterol Sulfate Hfa	Albuterol Sulfate	58	26
Estradiol	Estradiol	51	11
Bumetanide	Bumetanide	50	12
Lorazepam	Lorazepam	50	16
Montelukast Sodium	Montelukast Sodium	48	12
Alendronate Sodium	Alendronate Sodium	45	13
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	44	29
Venlafaxine Hcl Er	Venlafaxine Hcl	44	12
Glipizide Er	Glipizide	42	13
Ozempic	Semaglutide	42	11
Cephalexin	Cephalexin	41	17
Clonazepam	Clonazepam	41	suppressed
Finasteride	Finasteride	41	12
Famotidine	Famotidine	40	19
Metformin Hcl Er	Metformin Hcl	40	15
Pravastatin Sodium	Pravastatin Sodium	40	11
Meloxicam	Meloxicam	39	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	39	suppressed
Azithromycin	Azithromycin	37	29
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	36	11
Bupropion Xl	Bupropion Hcl	35	suppressed
Paroxetine Hcl	Paroxetine Hcl	35	suppressed
Warfarin Sodium	Warfarin Sodium	35	suppressed
Carvedilol	Carvedilol	34	suppressed
Celecoxib	Celecoxib	33	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Lovastatin	Lovastatin	32	suppressed
Spironolactone	Spironolactone	32	suppressed
Colchicine	Colchicine	31	17
Morphine Sulfate Er	Morphine Sulfate	30	suppressed
Synthroid	Levothyroxine Sodium	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Donepezil Hcl	Donepezil Hcl	29	suppressed
Methocarbamol	Methocarbamol	28	suppressed
Glipizide	Glipizide	26	suppressed
Enalapril Maleate	Enalapril Maleate	25	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Fenofibrate	Fenofibrate	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	11
Pregabalin	Pregabalin	23	suppressed
Diazepam	Diazepam	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Dutasteride	Dutasteride	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Oxycontin	Oxycodone Hcl	21	suppressed
Valsartan	Valsartan	21	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Glimepiride	Glimepiride	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Primidone	Primidone	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Digoxin	Digoxin	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Topiramate	Topiramate	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	12
Acyclovir	Acyclovir	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Xifaxan	Rifaximin	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Nitroglycerin	Nitroglycerin	13	13
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Testosterone	Testosterone	12	suppressed
Fentanyl	Fentanyl	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Mesalamine Er	Mesalamine	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error